Skip to main content

Table 3 The clinical outcomes between two groups

From: Long-term efficacy and safety of anticoagulant for cavernous transformation of the portal vein cirrhotic patient with extrahepatic portal vein obstruction

Variables

Anticoagulation group (n = 46)

Control group (n = 38)

P value

Hepatic decompensation

6 (13.0%)

13 (34.2%)

0.021*

Variceal bleeding

3 (6.5%)

8 (21.1%)

0.046*

Ascite

2 (5.5%)

2 (4.3%)

0.845

Hepatic encephalopathy

1 (2.1%)

1 (2.6%)

0.891

Infectious peritonitis

0

2 (5.3%)

Death

3 (6.5%)

9 (23.7%)

0.025*

Liver failure

1 (2.1%)

4 (10.5%)

0.097

Hemorrhoea

0

3 (7.9%)

Infectious peritonitis

1 (2.1%)

2 (5.3%)

0.425

Renal failure

1 (2.1%)

0

  1. indicates significance of P<0.05